R1 RCM Inc

R1 RCM — Corporate Update (June 2022)

13 slides from R1 RCM's corporate update, Jun 27, 2022

  1. Slide 1: Guidance Update Call

    Guidance Update Call NEED NEW IMAGE THAT WE SENT June 27, 2022 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation includes information that may constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking

  3. Slide 3: Presenters

    3 Lee Rivas President Presenters Joseph Flanagan Chief Executive Officer Rachel Wilson Chief Financial Officer & Treasurer

  4. Slide 4: Transaction Recap and Cloudmed Update

    4 Transaction Recap and Cloudmed Update

  5. Slide 5: Strategic and Financial Highlights

    5 Leading data and analytics-driven revenue intelligence platform Leading end-to-end technology- driven platform to manage healthcare provider revenue Powerful Combination of Market-leading Platforms ▪ Accelerates growth by unlocking full market potential ▪ Extends leadership in revenue cycle automa

  6. Slide 6: Transaction Close Summary

    6 Management and Board ▪ CEO: Joe Flanagan ▪ President: Lee Rivas ▪ Three new directors joined R1’s Board: ▪ Kyle Armbrester, CEO of Signify Health ▪ Jeremy Delinsky, COO of Devoted Health ▪ Matthew Holt, MD and President, Private Equity of New Mountain Capital Timing and Share Issuance ▪ Transactio

  7. Slide 7: President's Update

    7 Integration Execution on Track ▪ Sales teams integrated; significant opportunity across combined customer base ▪ Combined technology architecture creates leading RCM platform ▪ Cost synergy plans developed and realization is on track Cloudmed Executing Ahead of Plan ▪ Cross-sell execution combined

  8. Slide 8: Guidance Update

    8 Guidance Update

  9. Slide 9: 2022 Guidance Bridge

    9 2022 Guidance Bridge Note: Adjusted EBITDA is a non-GAAP measure; please refer to the Appendix for more information and a reconciliation of historical non-GAAP financial measures. $1,660 - $1,700 $1,850 - $1,870 $470 - $480 ($ in millions) $385 - $405 ~$70 ~$240 ~$9 ~$13 ~$105 Standalone Guidance

  10. Slide 10: Expected 2022 Quarterly Adjusted EBITDA Progression

    10 Expected 2022 Quarterly Adjusted EBITDA Progression Note: Adjusted EBITDA is a non-GAAP measure; please refer to the Appendix for more information and a reconciliation of historical non-GAAP financial measures. ▪ Q2 expected Adjusted EBITDA of $85-87 million reflects contribution from Cloudmed an

  11. Slide 11: Financial Outlook Post-2022

    11 Financial Outlook Post-2022 End-to-End NPR Growth 12-14%1 Modular Revenue Growth ~20% Adjusted EBITDA Growth 17%+ Medium-Term Adj. EBITDA Margin Target2 30%+ Long-Term Adj. EBITDA Margin Target 35%+ Note 1: Assumes $10B NPR contract is split between 2022 and 2023. Note 2: Medium-term is defined a

  12. Slide 12: Appendix

    endix p Ap ©) al

  13. Slide 13: Use of Non-GAAP Financial Measures

    13 Use of Non-GAAP Financial Measures ▪ In order to provide a more comprehensive understanding of the information used by R1’s management team in financial and operational decision making, the Company supplements its GAAP consolidated financial statements with certain non-GAAP financial performance

R1 RCM — Corporate Update (June 2022) on 6ix